Trial Profile

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vepugratinib (Primary) ; Enfortumab vedotin; Pembrolizumab
Indications Carcinoma; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms FORAGER-1
Sponsors Eli Lilly and Company

Most Recent Events

13 Oct 2025 According to an Eli Lilly and Company media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting, taking place October 17-21 in Berlin, Germany.
17 Apr 2025 Planned End Date changed from 1 Jun 2025 to 1 Jun 2027.
17 Apr 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com